国家医疗保障局局长章轲：中国必将成为全球最重要的创新药首发地

Core Viewpoint - The National Medical Insurance Administration emphasizes the role of the medical insurance fund as a stable financial source for innovation in the pharmaceutical industry, asserting that China will become a global leader in innovative drug development and pricing [1][8]. Group 1: Support for Innovation - The medical insurance system is seen as a driving force for pharmaceutical innovation, with a commitment to support high-quality development in the sector [1][8]. - The total medical insurance expenditure during the 14th Five-Year Plan period is projected to reach approximately 13 trillion RMB, maintaining an annual growth rate of over 10%, which provides substantial funding for industry innovation [2][9]. - The National Medical Insurance Administration has introduced 16 measures to support the high-quality development of innovative drugs, aiming to secure additional resources and development space for these products [3][10]. Group 2: Policy and Regulatory Framework - A comprehensive policy framework has been established, covering drug pricing, procurement, and reimbursement, which supports the entire process of pharmaceutical innovation from product initiation to regulatory evaluation [2][9]. - The dynamic adjustment mechanism for medical service pricing has been implemented, with over 4,600 billion RMB spent on negotiated drugs, leading to sales exceeding 6,000 billion RMB [4][11]. Group 3: Market Mechanisms and Application Scenarios - The National Medical Insurance Administration is actively developing application scenarios based on medical insurance data, including the establishment of a national medical imaging cloud by 2027 to enhance resource utilization and patient convenience [5][12]. - The administration has collected over 90 billion data entries related to drug traceability, ensuring quality and safety throughout the drug lifecycle [5][12]. - New verification scenarios are being established to support the integration of technology and healthcare, including AI-assisted diagnostics and health management systems [6][13]. Group 4: Future Outlook - The National Medical Insurance Administration aims to leverage China's large market, complete industrial system, and rich talent resources to build a diversified payment system and enhance data-driven support for pharmaceutical innovation [7][14].